Phase 1/2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Multiple Ascending Dose (Part 1) and Optional Dose Expansion (Part 2) Study of INV-102 Ophthalmic Solution in Adult Subjects With Moderate Symptomatic Dry Eye Disease
Latest Information Update: 11 Apr 2024
At a glance
- Drugs INV-102-Invirsa (Primary)
- Indications Dry eyes
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Invirsa
Most Recent Events
- 26 Jun 2023 Status changed from active, no longer recruiting to completed.
- 14 Jun 2023 According to an Invirsa media release, the company announced the closing of a $7.7 million Series B financing completed in April earlier this year. These funds will support this study and Phase 3 preparation.
- 18 Apr 2023 Status changed from recruiting to active, no longer recruiting.